Anleptic CR200 mg

Anleptic CR is an anticonvulsant and mood-stabilizing agent with established uses across several conditions, supported by different levels of clinical evidence:

Established / FDA-approved uses

• Epilepsy — treatment of partial seizures with complex symptomatology (psychomotor, temporal lobe), generalized tonic-clonic seizures, and mixed seizure patterns. Anleptic CR is not effective for absence (petit mal) seizures and may worsen them.
• Trigeminal neuralgia — treatment of pain associated with true trigeminal neuralgia.
• Bipolar I disorder — treatment of acute manic and mixed episodes (extended-release formulations).

Guideline-supported / off-label uses

• Neuropathic pain syndromes other than trigeminal neuralgia (e.g., glossopharyngeal neuralgia, diabetic neuropathy) — used off-label based on clinical guidelines and specialist experience.
• Prophylaxis of bipolar disorder as a maintenance/mood-stabilizing agent, generally as an adjunct when first-line agents are unsuitable.

Use of Anleptic CR for any indication should be individualized and supervised by a physician.

Each tablet/capsule of Carbamazepine contains Carbamazepine USP as the active pharmaceutical ingredient. Carbamazepine is available in conventional (immediate-release), chewable, extended-release tablet/capsule, and oral suspension formulations, in various strengths (commonly 100 mg, 200 mg, and 400 mg for tablets, and 100 mg/5 mL for oral suspension). Excipients vary by manufacturer and formulation.

Anleptic CR is an iminostilbene derivative, chemically related to the tricyclic antidepressants, that has been used for decades as an anticonvulsant and mood stabilizer. It is a first-line agent for partial and generalized tonic-clonic seizures and is also the primary drug used for trigeminal neuralgia. Beyond epilepsy, Anleptic CR is used to control acute manic and mixed episodes of bipolar I disorder.

Anleptic CR is a potent inducer of hepatic cytochrome P450 enzymes, which underlies many of its clinically significant drug interactions, and its own metabolism is subject to autoinduction over the first weeks of therapy.

Anticonvulsant (Antiepileptic); Mood Stabilizer. Anleptic CR belongs to the iminostilbene chemical class of antiepileptic drugs.

Carbamazepine's precise mechanism of action is not completely understood, but it is believed to act primarily by blocking voltage-gated sodium channels in neuronal membranes. This stabilizes hyperexcitable neuronal membranes, inhibits repetitive neuronal firing, and reduces the propagation of synaptic impulses, thereby reducing seizure activity and neuropathic pain transmission.

Pharmacokinetics

• Absorption: Slowly and variably absorbed after oral administration; food does not significantly affect the extent of absorption.
• Distribution: Approximately 76% bound to plasma proteins; crosses the placenta and is distributed into breast milk.
• Metabolism: Extensively metabolized in the liver, primarily via CYP3A4, to an active epoxide metabolite. Carbamazepine induces its own metabolism (autoinduction), so plasma clearance increases over the first few weeks of treatment.
• Elimination half-life: Initially 25–65 hours, decreasing to 12–17 hours with repeated dosing due to autoinduction.
• Excretion: Primarily via urine as metabolites, with a small fraction excreted unchanged.

Anleptic CR should be taken orally, preferably with food, at consistent times each day. Extended-release forms must be swallowed whole. Do not stop Anleptic CR abruptly without consulting a physician, as sudden discontinuation can precipitate seizures.

Anleptic CR is a strong inducer of CYP3A4 and other hepatic enzymes, leading to numerous clinically significant interactions:

• Monoamine oxidase inhibitors (MAOIs): Contraindicated; discontinue MAOIs at least 14 days before starting Anleptic CR.
• Nefazodone: Contraindicated combination due to loss of nefazodone efficacy and increased Anleptic CR levels.
• CYP3A4 inhibitors (e.g., erythromycin, clarithromycin, azole antifungals, diltiazem, verapamil, cimetidine, protease inhibitors, grapefruit juice): May significantly increase Anleptic CR levels, raising toxicity risk (dizziness, ataxia, diplopia).
• CYP3A4 inducers (e.g., rifampin, phenobarbital, phenytoin, felbamate): May decrease Anleptic CR levels and reduce efficacy.
• Hormonal contraceptives: Anleptic CR reduces efficacy of oral contraceptives due to enzyme induction; alternative or additional contraception is recommended.
• Warfarin and other anticoagulants: Anleptic CR reduces anticoagulant effect; monitor INR closely.
• Other antiepileptics (valproate, lamotrigine, phenytoin): Complex bidirectional interactions affecting levels of both drugs; monitoring required.
• Other drugs with reduced efficacy due to induction: corticosteroids, methadone, tricyclic antidepressants, some benzodiazepines, theophylline, and others.

Inform your physician of all medications, supplements, and herbal products before starting Anleptic CR.

Serious warnings (see Precautions and Warnings for full detail): severe dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) and blood dyscrasias (aplastic anemia, agranulocytosis).

Common side effects

• Dizziness, drowsiness, unsteadiness (ataxia)
• Nausea, vomiting
• Double or blurred vision (diplopia)
• Headache
• Mild skin rash

Less common but serious side effects

• Hyponatremia (due to SIADH-like effect)
• Blood dyscrasias — leukopenia, thrombocytopenia, aplastic anemia, agranulocytosis (see Precautions)
• Hepatotoxicity — abnormal liver function, jaundice, hepatitis
• Cardiac conduction disturbances (AV block, arrhythmias)
• Severe skin reactions — SJS/TEN, exfoliative dermatitis, drug reaction with eosinophilia and systemic symptoms (DRESS) (see Precautions)
• Pancreatitis

Anleptic CR is a well-established teratogen and has been associated with an increased risk of congenital malformations, including neural tube defects (e.g., spina bifida), craniofacial defects, cardiovascular malformations, and developmental delay when used during pregnancy. Anleptic CR should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; monotherapy at the lowest effective dose is preferred over combination antiepileptic therapy. Folic acid supplementation before and during pregnancy is recommended to reduce the risk of neural tube defects. Do not stop Anleptic CR without consulting a physician, as uncontrolled seizures also pose risks to mother and fetus.

Anleptic CR is excreted into breast milk. Use during breastfeeding should be under medical supervision, with the infant monitored for sedation, poor feeding, or adequate weight gain; consult a physician to weigh benefits and risks.

Serious Dermatologic Reactions

Anleptic CR can cause serious and sometimes fatal dermatologic reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The risk is significantly higher in patients with the HLA-B*1502 allele, which is more prevalent in individuals of Han Chinese, Thai, Malaysian, and certain other Asian ancestries. Genetic testing for HLA-B*1502 is recommended before starting Anleptic CR in patients from at-risk populations; patients testing positive should not be given Anleptic CR unless the benefit clearly outweighs the risk.

Blood Dyscrasias

Anleptic CR carries a risk of aplastic anemia and agranulocytosis that is several times higher than in the general population. Baseline complete blood count is recommended before starting therapy, with periodic monitoring thereafter. Patients should be advised to report immediately any signs of infection, fever, sore throat, easy bruising, or bleeding.

Hepatotoxicity

Liver function should be assessed at baseline and monitored periodically, as Anleptic CR can cause abnormal liver function tests, hepatitis, and rarely hepatic failure.

Hyponatremia

Anleptic CR can cause syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to hyponatremia; monitor sodium levels, particularly in elderly patients and those on diuretics.

Suicidal Behavior and Ideation

Antiepileptic drugs, including Anleptic CR, may increase the risk of suicidal thoughts or behavior. Monitor for mood changes, worsening depression, or unusual behavior changes.

Withdrawal

Do not discontinue Anleptic CR abruptly, as this may precipitate seizures or status epilepticus; discontinuation should be gradual under medical supervision.

Driving/Operating Machinery

Anleptic CR can cause dizziness and drowsiness; caution advised until individual response to the drug is known.

Symptoms of Anleptic CR overdose may include irregular breathing, drowsiness progressing to unconsciousness, restlessness, muscle twitching or tremor, involuntary movements, blurred vision, slurred speech, nausea, vomiting, cardiac conduction abnormalities (arrhythmias, hypotension), and seizures. Overdose can be life-threatening.

If overdose is suspected, seek immediate medical attention or contact emergency services/poison control right away. Treatment is supportive and should be provided in a hospital setting; there is no specific antidote. Do not attempt home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Anleptic CR is approved for use in children for epilepsy, with dosing based on age and body weight (see Dosage and Administration). Safety and efficacy for trigeminal neuralgia and bipolar disorder have not been established in the pediatric population; use for these indications in children is generally not recommended outside specialist guidance.

Elderly

Elderly patients may be more susceptible to Anleptic CR-related confusion, agitation, cardiac conduction disturbances, and SIADH/hyponatremia. Use with caution, starting at lower doses with close monitoring.

Hepatic Impairment

Use with caution; consider dose reduction and monitor liver function, as Anleptic CR is extensively hepatically metabolized.

Renal Impairment

No formal dose adjustment established; use with caution and monitor clinically and, where available, with plasma level monitoring.

Duration of Anleptic CR therapy is individualized based on indication and clinical response. For epilepsy, treatment is often long-term, with periodic physician reassessment of continued need. For trigeminal neuralgia, attempts to reduce or discontinue the dose should be made at approximately 3-month intervals to check if the condition has remitted. For bipolar disorder, duration is determined by the treating psychiatrist based on response and relapse risk. Do not stop or change the duration of treatment without consulting your physician.

Anticonvulsants; Iminostilbene derivatives; Mood stabilizers

Carbamazepine primarily blocks voltage-gated sodium channels, stabilizing the inactivated state of the channel and reducing high-frequency repetitive neuronal firing. This limits the spread of seizure activity from an epileptic focus and reduces neuropathic pain signal transmission. It may also affect synaptic transmission and reduce polysynaptic responses, contributing to its anticonvulsant and analgesic effects.

D

Anleptic CR is indicated for epilepsy (partial seizures, generalized tonic-clonic seizures, mixed seizure patterns) in children, including those as young as infants under specialist supervision, with dosing individualized by age and weight (see Dosage and Administration). Safety and efficacy of Anleptic CR for trigeminal neuralgia and bipolar disorder have not been established in children. Children should be monitored closely for the same serious risks as adults (severe skin reactions, blood dyscrasias), and baseline/periodic blood counts are recommended.